Spotlight on tumor mutation burden

We have witnessed great advancements for cancer over the past few years, namely immunotherapy. Despite this success, the use of these drugs remains imprecise, with a limited ability to identify patients who will benefit from treatment. Tumor mutational burden (TMB) is promising as a predictive biomarker and could potentially lead the way for immuno-oncology to enter an era of precision medicine.